Products classification
ABOUT US
Email:
sales@ruixibiotech.com
Tel.:
02988811435
Home > products > apis> gpcr-g-protein
Catalog name Description price
R-C-2540 Ki16198 CAS：355025-13-7 Ki16198 is a potent and orally active LPA receptor antagonist,the methyl ester of Ki16425(HY-13285).Ki16198 inhibits LPA1 and LPA3-induced inositol phosphate production with Ki values of 0.34μM and 0.93μM,respectively.Ki16198 is effective for pancreatic cancer tumorigenesis and metastasis in vivo. price>
R-R-4240 Mavorixafor trihydrochloride CAS No.2309699-17-8 Mavorixafor trihydrochloride (AMD-070 trihydrochloride)/CAS No.2309699-17-8 is a potent, selective and orally available CXCR4 antagonist, with an IC50 value of 13 nM against CXCR4 125I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 1 and 9 nM, respectively. price>
R-R-4241 SCH 546738 CAS No.906805-42-3 SCH 546738/CAS No.906805-42-3 is a potent, orally active and non-competitive CXCR3 antagonist, the affinity constant (Ki) of SCH 546738 binding to human CXCR3 receptor is determined to be 0.4 nM in multiple experiments. price>
R-R-4242 SX-682 CAS No.1648843-04-2 SX-682/CAS No.1648843-04-2 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity. price>
R-R-4243 ACT-1004-1239 CAS No.2178049-58-4 ACT-1004-1239/CAS No.2178049-58-4 is a potent, selective, orally active CXCR7 antagonist with an IC50 value of 3.2 nM. price>
R-R-4244 NUCC-390 dihydrochloride CAS No.2749281-71-6 NUCC-390 dihydrochloride/CAS No.2749281-71-6 is a novel and selective small-molecule CXCR4 receptor agonist. NUCC-390 dihydrochloride induces internalization of CXCR4 receptors and acts in an opposite way of AMD3100 (HY-10046). NUCC-390 dihydrochloride promotes nerve recovery of function after neurodegeneration in vivo. price>
R-R-4245 SB-265610 CAS No.211096-49-0 SB-265610/CAS No.211096-49-0 is a selective, competitive, nonpeptide and allosteric CXCR2 antagonist. SB-265610 blocks rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization and neutrophil chemotaxis with IC50s of 3.7 nM and 70 nM, respectively. price>
R-R-4246 CXCR7 antagonist-1 CAS No.1613021-99-0 CXCR7 antagonist-1/CAS No.1613021-99-0 is a CXCR7 antagonist that inhibits the binding of the SDF-1 chemokine (also known as the CXCL12 chemokine) or I-TAC (also known as CXCL11) to the chemokine receptor CXCR7. CXCR7 antagonist-1 is useful in preventing tumor cell proliferation, tumor formation, inflammatory diseases, and many other diseases (extracted from patent WO2014085490A1, compound 1.128). price>
R-R-4247 ML 145 CAS No.1164500-72-4 ML 145/CAS No.1164500-72-4 is a selective and competitive human GPR35/CXCR8 antagonist with an IC50/EC50 of 20.1 nM. ML 145 has over 1000-fold more selective for GPR35 compared to GPR55 (IC50/EC50=21.7 μM). ML 145 has no significant activity for GPR35 at either rodent ortholog. price>
R-C-2548 TG6-10-1 CAS:1415716-58-3 TG6-10-1 is an EP2 antagonist,shows low-nanomolar antagonist activity against only EP2,>300-fold selectivity over human EP3,EP4,and IP receptors,100-fold selectivity over EP1 receptors. price>